Program Description & Educational Objectives

In this activity, an expert in the use of MRI discusses the appropriate selection and use of contrast imaging agents.

Upon completion of this activity, participants should be better able to:

• Apply the latest advances in the use of MRI technology and contrast media in patient evaluations and utilize available guidelines for performing and interpreting MRI
• Differentiate between current and novel MRI contrast agents, recognizing the indications for use of such different agents
• Determine which contrast agents are appropriate for use in renal-impaired patients and other special populations for whom gadolinium-based contrast agents are contraindicated or must be used with caution
• Employ strategies to appropriately manage adverse events associated with gadolinium-based contrast agents

Target Audience

This activity has been designed to meet the educational needs of radiologists, MRI technologists, and other clinicians involved in the use of contrast imaging agents.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: December 22, 2011 - December 21, 2012
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

All faculty AND staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

Course Director and Interviewee

Marco Essig, MD, PhD
Professor of Radiology
Heidelberg Medical School
Heidelberg, Germany
Department of Neuroradiology
University of Erlangen
Erlangen, Germany

Marco Essig, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant for Bayer HealthCare Pharmaceuticals; Medidata Solutions; and pharmtrace.

Grant/Research Support from Bayer HealthCare Pharmaceuticals and Bracco.

Honoraria from Bayer HealthCare Pharmaceuticals; b·e·imaging; Bracco; and Medidata Solutions.

Advisory Board for Bayer HealthCare Pharmaceuticals and Bracco.

Content Director

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.

All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University College of Pharmacy staff have no relationships to disclose.

Sponsorship, Credit & Support

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

The Purdue University College of Pharmacy designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is jointly sponsored by Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.